What To Expect From Fulgent Genetics In 2023 (NASDAQ:FLGT)

The company is continuing its Phase 1 clinical trial evaluating the efficacy of FID-007 in treating various types of cancer. See why FLGT stock is a Hold.

Related Keywords

Russia ,United States ,Ukraine ,China ,Ming Hsieh ,Bioreference Health ,Fulgent Genetic ,Wall Street ,Fulgent Genetics ,Quest Diagnostics ,Reference Health ,Inform Diagnostics ,Investor Presentation ,Fulgent Pharma ,